Promises
1 promise
Promise Tracker
0 delivered, 0 close, 1 missed.
View Promises →
Glenmark Pharmaceuticals Limited — Q2 FY26
Glenmark's Q2 FY26 consolidated revenue surged 76% YoY to INR 6,047 crore, driven by the ISB 2001 out-licensing income.
bullish
high
✓ Verified against BSE filing
2-Minute Summary
✦ AI-Generated from Full Transcript
Glenmark's Q2 FY26 consolidated revenue surged 76% YoY to INR 6,047 crore, driven by the ISB 2001 out-licensing income. Excluding this, US core business grew 7.4%. India formulation sales declined 9% due to GST-driven distributor destocking, but management expects a INR 1,150-1,200 crore quarterly run-rate from Q3. The company used the deal proceeds to repay all debt, becoming net cash positive, and discontinued high-cost pre-collection practices, which temporarily increased receivables. EBITDA margin guidance is 23%, targeting 25%+ over time. FY27 revenue guidance is INR 17,000-18,000 crore. Key risks include execution on the India distribution transition and potential future litigation costs.
ग्लेनमार्क की दूसरी तिमाही में कमाई 76% बढ़कर 6,047 करोड़ रुपये हो गई। इसकी मुख्य वजह ISB 2001 दवा के लाइसेंस से मिली कमाई है। इसके अलावा, अमेरिका में मुख्य कारोबार 7.4% बढ़ा। भारत में दवा बिक्री 9% गिरी, क्योंकि जीएसटी के कारण दुकानदारों ने स्टॉक कम किया। कंपनी को उम्मीद है कि तीसरी तिमाही से हर तिमाही 1,150-1,200 करोड़ रुपये की बिक्री होगी। कंपनी ने कर्ज चुकाकर शुद्ध कर्ज-मुक्त हो गई है। अब वह 23% मुनाफा कमाने का लक्ष्य रखती है, जो बाद में 25% से अधिक हो सकता है। अगले साल 17,000-18,000 करोड़ रुपये की कमाई का अनुमान है। मुख्य जोखिम भारत में नई बिक्री व्यवस्था और संभावित कानूनी खर्च हैं।
Promises0 met · 1 missedRisks3 trackedTranscriptfull text
Research workspace
Focused Modules
Risks
3 risks
Risk Intelligence
India distribution disruption from GST change
View Risks →
Transcript
Full text
Call Transcript
Full transcript text is available on this route.
Read Transcript →Quarter Snapshot
India secondary sales growth (IQVIA)
10.8%
+4.4pp vs market
Glenmark's India secondary sales grew 10.8% in Q2, outperforming the overall market growth of 6.4%.
US ANDA pipeline
53
25 para IV filings
53 ANDAs pending approval, including 25 para IV filings, supporting future US growth.
Rialtris commercialization count
49 markets
+49 markets vs prior
Rialtris is now commercialized in 49 markets, with China approval secured and launch expected H1 FY27.
IGI annual spend
INR 70-75 crore
self-funded for 3 years
IGI will spend INR 70-75 crore annually, funded from ISB 2001 proceeds, with no additional capital needed.
What Changed vs Last Quarter
NEW
India business Q3 run-rate of INR 1,150-1,200 crore
Management expects India formulation sales to return to INR 1,150-1,200 crore per quarter from Q3 FY26, with FY27 revenue exceeding INR 4,800 crore.
NEW
FY27 revenue guidance of INR 17,000-18,000 crore
Management guided for FY27 consolidated revenue of INR 17,000-18,000 crore, implying ~15% growth over FY26 run-rate.
NEW
Zero gross debt by end of FY26
Management targets zero gross debt by March 2026, with strong free cash flow generation from H2 FY26.
UPDATED
EBITDA margin target of 23% moving to 25%+
EBITDA margin to trend towards 23% immediately and strengthen to 25%+ over time, driven by discontinuation of pre-collections and operating leverage.
DROPPED
India business to grow 10-15% CAGR over 3-5 years
Management expects India business to grow at 10-15% CAGR over the next three to five years, driven by branded products and new launches.
DROPPED
Europe to return to double-digit growth from Q2 FY26
Management anticipates Europe region returning to double-digit growth from Q2 FY26 and expects double-digit growth for full year FY26.
DROPPED
Emerging markets double-digit growth in FY26 on constant currency
Management expects emerging markets to record double-digit growth in FY26 on a constant currency basis.
NEW RISK
India distribution disruption from GST change
The unexpected GST regime change caused a one-time reduction in distributor inventories, impacting primary sales. While management expects normalization, future regulatory changes could again disrupt the three-tier model.
NEW RISK
Recurrence of legacy balance sheet issues
Analysts questioned the frequency of write-offs (Monroe, litigation, India). Management assured no further corrections, but past unpredictability raises concerns about controls.
NEW RISK
Litigation cash outflows still pending
Management confirmed litigation cash outflows of slightly less than INR 800 crore over the next few years, which could pressure cash flows if not managed.
RISK GONE
Monroe facility FDA observations unresolved
The Monroe facility has five FDA observations; management is awaiting FDA response and hopes to restart commercial manufacturing this year, but timeline is uncertain.
RISK GONE
Antitrust litigation in US
Glenmark USA is involved in multidistrict antitrust litigation; settled with direct purchaser class for $37.75M, but other classes remain, with no visibility on timeline.
RISK GONE
India reported growth vs secondary sales divergence
India reported growth of 3.7% lags secondary sales growth of 15.1% due to tail-end brand discontinuations; convergence expected only from Q3.
RISK GONE
Net debt increase and working capital buildup
Net debt increased to INR 1,500 crore due to inventory buildup for launches and one-time payments; management expects stabilization but no specific timeline.
🤫 Topics management stopped discussing
Mentioned in Q1 FY25, Q2 FY25, Q4 FY25
EBITDA margin guided to 19%-20% for FY2026, driven by Ryaltris, U.S. launches, and R&D efficiencies.
Mentioned in Q1 FY26, Q3 FY25
Management expects emerging markets to record double-digit growth in FY26 on a constant currency basis.
Mentioned in Q1 FY26, Q4 FY25
Management anticipates Europe region returning to double-digit growth from Q2 FY26 and expects double-digit growth for full year FY26.
Mentioned in Q1 FY25, Q3 FY25
The Indian GLP-1 market is expected to become crowded, potentially limiting Glenmark's market share despite its first-mover advantage with Lirafit.
Mentioned in Q1 FY25, Q2 FY25
Management aims to initiate partnering discussions post-ASH 2024 and expects a deal by FY26.
Fast read
Guidance and risk preview
Management expects India formulation sales to return to INR 1,150-1,200 crore per quarter from Q3 FY26, with FY27 revenue exceeding INR 4,800 crore.
The unexpected GST regime change caused a one-time reduction in distributor inventories, impacting primary sales.
View Risks →